Diagnostic Medical shares surge more than 11% following its results
DMS Group shares are soaring during the session, driven by first-half 2026 results published the previous day that reveal a clear improvement in profitability despite a decline in activity. The stock is moving in a broadly downward market context, which makes the upward progression particularly notable.
First-half 2026 results showing marked profitability improvement
DMS Group published its first-half 2026 accounts on September 14, 2026: revenue declined by 6% over the period, but the medical imaging group has returned to a positive net result of €0.5m and an EBITDA margin of 11.7%, compared to 7.2% a year earlier. This turnaround in profitability contrasts with the contraction in revenues, and this is clearly the signal the market is taking on Tuesday. The company describes a cautious environment in Europe, with project and tender deferrals, which weighs on volumes but does not prevent structural margin improvement. When publishing first-half 2026 results (on July 20, 2026), Diagnostic Medical had identified among its growth drivers the progression of bone densitometry (+6% mid-year) and the launch of the ONYX mobile radiography system, while conventional radiography declined by 9% and North America by 15%.
An RSI in oversold territory amplifying the rebound against mixed moving averages
At €1.09, Diagnostic Medical shares are advancing 11.22% during the session, above its 20-day moving average at €1.02 (a gap of nearly +6.9%) and slightly above its 50-day moving average at €1.08 (+0.93%). However, the price remains below the 200-day moving average at €1.24, which caps the rebound with a negative gap of 12.10%. The RSI at 28, in a marked oversold configuration, provided favorable ground for this type of surge: a publication perceived positively by the market can trigger a rapid rebound when the stock is so technically compressed.
The immediate resistance to watch is at €1.10, within reach of the current price, while the 200-day moving average at €1.24 represents a significantly more distant horizon. Over three months, the stock is still down 14.84%, which illustrates the scale of the distance remaining if the fundamental improvement were to be confirmed in upcoming publications.
